|
|
|
Dear guest!
To access full content of this article, please take a minute to become a member of this site. As a registered user you will be able to view all of our vast archive's material at any time.
Sign up now!
Already registered? Please sign in.
Alternatively, please use our pay-per-view service. |
|
|
 |
Industry Events |
 |
Connect in Pharma
14-15 September 2022, Plaexpo, Geneva, Switzerland
The new event driving innovation for pharma and biopharma businesses,
Connect in Pharma will unite key players in Pharmaceutical and
Biopharmaceutical packaging and production in Geneva on 14 – 15
September 2022.
More info >> |
|
 |
News and Press Releases |
 |
European Medicines Agency Commences Review of Aripiprazole 2-Month Long-Acting Injectable for the Maintenance Treatment of Schizophrenia in Adult Patients Stabilised with Aripiprazole
LONDON, UK, 17 June 2022 – Otsuka Pharmaceutical Europe Ltd.
(“Otsuka”) and H. Lundbeck A/S (“Lundbeck”) today announce that the
European Medicines Agency (EMA) has accepted the Marketing Authorisation
Application (MAA) for aripiprazole as a 2-month ready-to-use (RTU)
long-acting injectable (LAI) for the maintenance treatment of
schizophrenia in adult patients stabilised with aripiprazole.
More info >> |
|
|
